Deciphera Pharmaceuticals, LLC

643 Massachusetts St Ste 200, Lawrence, Kansas, United States

Clinical Trials

27 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

78.4%

Phase 3

11.8%

Phase 2

2.0%

Trial Status Distribution

Active, not recruiting

52.9%

Approved For Marketing

2.0%

Completed

17.6%

Recruiting

15.7%

Terminated

9.8%

Withdrawn

2.0%

Clinical Trials

Trials sponsored by this organization (51)

Evaluate the Effect of Vimseltinib on P-glycoprotein (P-gp) Inhibition in Healthy Male Participants

Phase 1

Recruiting

interventional

Sep 202620 participants

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Phase 1

Recruiting

interventional

Jun 202624 participants

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Phase 1

Completed

interventional

Nov 202522 participants

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Phase 1

Completed

interventional

Oct 202520 participants

MOVE: Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

Recruiting

observational

Sep 2025100 participants

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

Phase 1

Recruiting

interventional

Aug 202560 participants

A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)

Phase 1

Recruiting

interventional

Dec 2024120 participants

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Phase 2

Recruiting

interventional

Nov 202448 participants

Page 1 of 7

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

Approvals

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations